Publications en collaboration avec des chercheurs de Instituto de Investigación Sanitaria Gregorio Marañón (121)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure

  3. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  4. Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells

    HemaSphere, Vol. 8, Núm. 7

  5. Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology

    Clinical and Translational Oncology

  6. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

  7. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease

  8. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217

  9. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology

  10. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437

  3. Autism care pathway in Europe

    European Psychiatry, Vol. 66, Núm. 1

  4. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

    Haematologica, Vol. 108, Núm. 1, pp. 110-121

  5. Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study

    Journal of Infection, Vol. 87, Núm. 1, pp. 46-53

  6. Chronic Venous Disease during Pregnancy Is Related to Inflammation of the Umbilical Cord: Role of Allograft Inflammatory Factor 1 (AIF-1) and Interleukins 10 (IL-10), IL-12 and IL-18

    Journal of Personalized Medicine, Vol. 13, Núm. 6

  7. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research

  8. Coronary Obstruction After Transcatheter Aortic Valve Replacement: Insights From the Spanish TAVI Registry

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 10, pp. 1208-1217

  9. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  10. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome

    British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314